Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$15.2MCash on Hand
5.7mo Cash Runway
Follow MDCX by emailGet an email when MDCX pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about MDCX, unsubscribe in one click. Privacy
🧪 Trial & FDA Catalysts
Aug 2014 · Phase 2 · Results Expected · MSM Product on Attenuating Nasal Provocation With a Standardized Allergenic Challenge Registry primary completion date, not a results date
Aug 2014 · Phase 2 · Results Expected · The Effects of the Onion-Pumpkin Extract on Blood Pressure Registry primary completion date, not a results date
Jun 2014 · Phase 1 · Results Expected · DEC033 Study Product for Mild to Moderate Eczema An Open-label, Adaptive-design Pilot Stud Registry primary completion date, not a results date
💰 Cash Runway & Dilution Risk
MDCX holds $15.2M in cash and short-term investments (as of Jun 30, 2026) and burns about $8M/quarter from operations,
an estimated runway of 5.7 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:50 · Elevated
Cash runway 6 months +40
Share count +255% in a year +20
Raised after last reported balance sheet (Sep 2026) -10
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MDCX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.